Sofosbuvir- Daclatasvir: Effectiveness among cirrhotic and non-cirrhotic genotype 1 to 4 HCV patients, in real world settings

Loarec A.; Fortas C.

首页> 外文期刊>Journal of viral hepatitis. >Sofosbuvir- Daclatasvir: Effectiveness among cirrhotic and non-cirrhotic genotype 1 to 4 HCV patients, in real world settings

【24h】

Sofosbuvir- Daclatasvir: Effectiveness among cirrhotic and non-cirrhotic genotype 1 to 4 HCV patients, in real world settings

机译：Sofosbuvir- daclatasvir：肝硬化和非肝硬化基因型1至4例HCV患者的有效性，在现实世界中设置

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Journal of viral hepatitis.》 |2018年第s2期|共1页
作者
Loarec A.; Fortas C.;
展开▼
作者单位

Epictr MSF Epidemiol &

Populat Hlth Paris France;

Epictr MSF Epidemiol &

Populat Hlth Paris France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Occult HCV Infection (OCI) Diagnosis in Cirrhotic and Non-cirrhotic Naive Patients by Intra-PBMC Nested Viral RNA PCR [J] . Mohamed Darwish Ahmed Abd Alla, Saleh Ahmed Elibiary, George Y.Wu, 临床与转化肝病杂志（英文版） . 2017,第004期
2. Efficacy and Safety of Ombitasvir plus Paritaprevir,Ritonavir and Ribavirin in Non-cirrhotic Treatment-naive and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection [J] . Manar Ahmed, Azza E.Mansey, Engy A.Wahsh, 当代医学科学(英文) . 2021,第003期
3. LBP‐006: Sofosbuvir‐ Daclatasvir: Effectiveness among cirrhotic and non‐cirrhotic genotype 1 to 4 HCV patients, in real world settings [J] . Journal of viral hepatitis. . 2018,第S1期

机译：LBP-006：Sofosbuvir-daclataSvir：肝硬化和非肝硬化基因型1至4例HCV患者的有效性，在现实世界中设置
4. Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naive non-cirrhotic patients with chronic HCV Genotype 3 Infection [J] . Hezode Christophe, Leroy Vincent, Rosa Isabelle, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：Sofosbuvir和Daclatasvir在治疗 - 幼稚非肝硬化患者慢性HCV基因型3感染患者8周的疗效和安全性
5. Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naive non-cirrhotic patients with chronic HCV Genotype 3 Infection [J] . Hezode Christophe, Leroy Vincent, Rosa Isabelle, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：Sofosbuvir和Daclatasvir在治疗 - 幼稚非肝硬化患者慢性HCV基因型3感染患者8周的疗效和安全性
6. Hepatitis C Virus Genotyping and Serum Anti-F Antibody Detection of HCV Patients in the South of Jiangsu Province of China [C] . Xiao-Zhao Deng, Yun Zhang, Zhen-Yu Diao, International Forum on Progress on Post-Genome Technologies(5'IFPT); 20070910-11; Suzhou(CN) . 2007

机译：苏南地区丙型肝炎患者丙型肝炎病毒基因分型和血清抗F抗体检测
7. Effectiveness of child life intervention on uncooperative pediatric patients in the dental clinic setting. [D] . Hinze, Ty Andrew. 2010

机译：儿童生活干预对牙科诊所环境中不合作的小儿患者的有效性。
8. Eight-week ledipasvir/sofosbuvir in non-cirrhotic treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA 6 million: Single center real world effectiveness and safety [O] . Nyan L Latt, Beshoy T Yanny, Derenik Gharibian, 2017

机译：八周的ledipasvir / sofosbuvir在非肝硬化未接受过治疗的C型基因型1型丙型肝炎病毒-RNA 600万的患者中：单中心实际有效性和安全性
9. Cost Effectiveness Analysis of The Use of Daclatasvir for the Treatment of Hepatitis C Virus (Hcv) Genotypes 3 in Cirrhotic Patients Within the Italian National Health Service [O] . Restelli, U, Bonfanti, M, Alberti, A, 2015

机译：在意大利国家卫生服务部门使用达克他韦治疗肝硬化患者的丙型肝炎病毒（Hcv）基因型3的成本效益分析

Sofosbuvir- Daclatasvir: Effectiveness among cirrhotic and non-cirrhotic genotype 1 to 4 HCV patients, in real world settings

著录项

引文网络

相似文献

相关主题

期刊订阅